REG - N4 Pharma PLC - Collaboration Agreement with SRI International Inc

N4 PharmaAnnouncement

25/04/2024 07:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240425:nRSY0062Ma&default-theme=true

RNS Number : 0062M  N4 Pharma PLC  25 April 2024

 25 April 2024

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

Collaboration Agreement with SRI International Inc.

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system designed to carry nucleotides to be developed
as cancer treatments and vaccines, is delighted to announce that it has
entered into a research collaboration agreement (the "Agreement") with SRI
International, an independent nonprofit research institute based in Silicon
Valley, California ("SRI") to combine Nuvec® with SRI's proprietary FOX Three
Molecular Guidance System™ ("MGS") with the aim of co-marketing the
resultant combined technology.

 

Under the Agreement, the Company will collaborate with SRI to perform research
to conjugate its MGS system to Nuvec® in order to increase intracellular
delivery to specific target cells. On the back of the combined technology, N4
Pharma and SRI will work collaboratively to develop and pursue new business
opportunities.

 

SRI's MGS technology is designed to overcome cellular barriers that prevent
intracellular delivery of large molecule biotherapeutics. The system uses
proprietary technology that enables the delivery of macromolecular payloads to
the target cell and then on to subcellular locations within those cells. SRI
has developed a panel of 50 MGSs targeted at a wide variety of cell types,
both diseased and healthy.

 

SRI has demonstrated that the MGS technology can deliver more than a dozen
types of payloads - from functional enzymes, antibodies, and nucleic acids
(including siRNA, ASOs, and DNA) to liposomes and nanoparticles - to targeted,
intracellular molecular-target locations previously considered unreachable,
and therefore, untreatable. For more information on MGS see:
https://www.sri.com/platform/fox-three-molecular-guidance-system-mgs/
(https://www.sri.com/platform/fox-three-molecular-guidance-system-mgs/) .

 

The SRI Biosciences division the Company will be working with integrates basic
biomedical research with drug and diagnostics discovery, and preclinical and
clinical development. The team has advanced more than 200 drugs to clinical
trials, and 25 have reached the market. The division is focused on novel
platforms and programs in a variety of therapeutic areas targeting high unmet
medical needs.

 

Kathlynn Brown, President of SRI's Bioscience Division, commented:

 

"We're excited to work with N4 Pharma to advance nucleic acid therapies and
expand the number of applications of their Nuvec nanoparticle technology using
the FOX Three Platform. The key properties of Nuvec, including preventing
enzymatic breakdown of nucleotides and large surface area allowing multiple
copy number of cargo, together with the targeting provided by MGS, may
significantly enhance the use of nucleotide therapies. This partnership marks
an exciting journey towards expanding treatment possibilities and transforming
the landscape of biomedicine."

 

Nigel Theobald, Chief Executive Officer of the Company, commented:

 

"We are delighted to be working with SRI and to have entered into this
collaboration agreement. Combining our technologies successfully will lead to
working with major pharma companies in the fields of oncology and vaccines
with the exciting potential to develop novel products.

 

"SRI collaborates with a broad range of partners from small and virtual
biotechnology companies to top ten pharmaceutical companies and other leading
industry partners, which will give us unparalleled access to potential
commercial partners on the back of any successful combined technology
resulting from our research.

 

This marks an exciting new chapter for N4 Pharma and I look forward to
providing further updates as the research work progresses, as well as on our
other work streams such as oral applications of Nuvec® and the development of
ECP105 for an orphan indication with Nanogenics."

 

About SRI

SRI is an independent, global leader in R&D with deep roots in Silicon
Valley. It is a nonprofit research institute, headquartered in Menlo Park,
Calif., with a rich history of supporting government and industry. Its
objective is to create and deliver world-changing solutions for a safer,
healthier, and more sustainable future. For more than 75 years, SRI has
collaborated across technical and scientific disciplines to discover and
develop groundbreaking products and technologies and bring innovations and
ideas to the marketplace. Learn more at www.sri.com
(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sri.com%2F&esheet=53386511&newsitemid=20230424005677&lan=en-US&anchor=www.sri.com&index=6&md5=adb754ee9be7e41c4e1fbdc62b8e63bc)
.

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                  Via N4 Pharma Investor Hub

 Luke Cairns, Executive Director

 Engage with us directly at N4 Pharma Investor Hub                    Sign up at investors.n4pharma.com (https://investors.n4pharma.com/)
 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                Tel: +44(0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope

 

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at investors.n4pharma.com
(https://investors.n4pharma.com/) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRSEMSMIELSEDL